Basel, Switzerland, July 12, 2023 €“ Kinarus Therapeutics Holding AG (€œKinarus€) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Basel, Switzerland, May 10, 2023 â“ Kinarus Therapeutics Holding AG (âœKinarusâ) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced that it has engaged with Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, a global conglomerate from China, to explore partnering options to initiate phase 2 testing of KIN001 to treat wet age-related macular degeneration (wAMD) and idiopathic pulmonary fibrosis (IPF). In addition, Kinarus and GHCG will explore further business opportunities which may include licensing or strategic partnerships. Kinarus sees multiple opportunities for KIN001 in indications with high unmet need are well-matchedto the Chinese market.
Basel, Switzerland, 16 November 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced today that it has engaged Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, a global conglomerate from China, to explore partnering options to initiate Phase 2 testing of KIN001 to treat wet age-related macular degeneration (wAMD) and idiopathic pulmonary fibrosis (IPF). In addition, Kinarus and GHCG will explore further business opportunities which may include licensing or strategic partnerships.
Kinarus Therapeutics has dosed the first subject in the Phase II KINFAST clinical trial of the orally administered drug combination KIN001 in people with mild or moderate Covid-19 in an outpatient setting.